Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $73.38 Consensus Price Target from Brokerages

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have received an average rating of “Buy” from the ten ratings firms that are presently covering the stock, MarketBeat.com reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $73.38.

A number of equities research analysts have issued reports on the company. Royal Bank of Canada restated an “outperform” rating and set a $68.00 price target on shares of Jasper Therapeutics in a research note on Monday, December 23rd. JMP Securities reissued a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a report on Monday. HC Wainwright reiterated a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research report on Thursday, October 24th. Finally, BMO Capital Markets started coverage on Jasper Therapeutics in a research report on Friday, December 6th. They issued an “outperform” rating and a $63.00 target price on the stock.

Jasper Therapeutics Trading Down 15.1 %

Shares of JSPR stock opened at $17.71 on Wednesday. Jasper Therapeutics has a 12-month low of $6.61 and a 12-month high of $31.01. The stock has a market capitalization of $265.67 million, a P/E ratio of -3.74 and a beta of 2.18. The firm’s 50 day moving average is $21.95 and its 200 day moving average is $20.46.

Hedge Funds Weigh In On Jasper Therapeutics

A number of large investors have recently made changes to their positions in the company. BNP Paribas Financial Markets grew its stake in shares of Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after buying an additional 1,698 shares during the last quarter. Wolff Wiese Magana LLC purchased a new position in Jasper Therapeutics during the 3rd quarter valued at $59,000. MetLife Investment Management LLC grew its position in Jasper Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after acquiring an additional 3,873 shares during the last quarter. Jane Street Group LLC purchased a new stake in Jasper Therapeutics in the third quarter worth $251,000. Finally, Rhumbline Advisers bought a new stake in shares of Jasper Therapeutics during the second quarter worth $300,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.